Introduction
============

Cancer remains one of the leading causes of human death worldwide. Although significant progress has been made in cancer biology, genomics, proteomics, and clinical oncology during the past several decades, anticancer treatments are unsatisfactory and the overall survival of many cancer patients stays low.[@b1-ijn-13-2921] Chemotherapy is one of the most commonly used cancer treatment options in the clinic. Typically, chemotherapy drugs are toxic chemicals and administrated systemically via either parenteral or oral routes. However, these drugs often have drawbacks, including poor solubility and bioavailability, unfavorable pharmacokinetics, and nonselective biodistribution, which may complicate their clinical use and lead to undesirable side effects.[@b2-ijn-13-2921],[@b3-ijn-13-2921]

The nanotechnology-based medicines, that is, nanomedicines, have shown excellence in drug delivery, diagnosis, and therapy, particularly in cancer research. Nanoscale drug delivery systems (NDDSs) or nanocarriers play an important role in nanomedicine to overcome the aforementioned drawbacks of chemotherapy drugs. Compared to traditional drug delivery systems, nanocarriers have shown greater potential in improving drug bioavailability, prolonging drug circulation time, controlling drug release, and targeting tumor. In addition to performing these basic functions, the newly emerging technology and nanomaterials may offer extra functions or opportunities to nanomedicines/nanocarriers for various purposes of cancer diagnosis and treatments.[@b4-ijn-13-2921],[@b5-ijn-13-2921] Various nanocarriers have been developed, of which the most commonly studied are the organic nanocarriers, such as liposomes, polymeric micelles (PMs), and dendrimers, and inorganic nanocarriers, such as carbon nanotubes, silica nanoparticles, gold nanoparticles, magnetic nanoparticles, and quantum dots.[@b6-ijn-13-2921],[@b7-ijn-13-2921]

PMs are one of the first polymeric self-assemblies. Over the past few decades, they have received tremendous attention in biomedical sciences, especially as drug carriers, since they provide several physicochemical and biological advantages over other types of nanoassemblies, including easy preparation, simple architecture, drug solubilization, improved biocompatibility, pharmacokinetics, and biodistribution, and additional opportunities for further engineering.[@b8-ijn-13-2921],[@b9-ijn-13-2921] It is worth noting that several drug-loaded PM formulations have been approved for clinical trials for cancer treatments, and some PMs showed the promising anticancer activity ([Table 1](#t1-ijn-13-2921){ref-type="table"}).[@b10-ijn-13-2921],[@b11-ijn-13-2921] For instance, Genexol^®^-PM is a paclitaxel (PTX)-loaded PM formulation which consists of a block copolymer, poly(ethylene glycol) (PEG)-poly([d]{.smallcaps},[l]{.smallcaps}-lactide) (PLA). PTX is one of the most commonly used chemotherapy drugs for treating ovarian, breast, lung, cervical, and pancreatic cancers. However, it has very low water solubility and is currently used as a solution in Cremophor EL/ethanol (1:1, w/w). Unfortunately, the Cremophor may cause unwanted side effects such as hypersensitivity, nephrotoxicity, and neu-rotoxicity. Moreover, the dose-limiting toxicity such as neuropathy and neutropenia is another concern. In preclinical studies, Genexol-PM demonstrated a threefold increase in the maximum tolerated dose and a significantly increased antitumor efficacy compared with free PTX. Currently, a number of clinical studies over Genexol-PM are underway.

In order to exert anticancer effects, drugs have to be released from the PMs efficiently and specifically in tumor tissues or inside tumor cells. However, highly stable PMs may result in slow and incomplete drug release and lower the efficacy of the loaded drugs. Therefore, various stimuli-responsive PMs have been developed for "smartly" controlling drug release as well as drug efficacy.[@b12-ijn-13-2921],[@b13-ijn-13-2921] The idea of stimuli-responsive drug delivery systems comes from the fact that the tumor tissue possesses a variety of unique features compared with the normal tissue, including acidic pH, altered redox potential, and overexpressed proteins and enzymes. In addition, stimuli such as temperature, light, ultrasound, and magnetic fields can be applied to the tumor site externally to allow PMs to bypass the biological barriers, reach their targets, and release their loaded drugs. This article aims to summarize and discuss the recent advances of stimuli-responsive PMs in drug delivery and cancer therapy.

Polymeric micelles
==================

PMs are spherical colloidal particles with a size typically ranging from 10 to 100 nm. They are composed of amphiphilic copolymers that have distinct hydrophobic and hydrophilic blocks.[@b14-ijn-13-2921] Usually, these copolymers are amphiphilic di-block (hydrophilic--hydrophobic) or tri-block (hydrophilic--hydrophobic--hydrophilic) polymers. The most commonly used hydrophilic blocks are PEG with a molecular weight of 2--15 kDa, while the hydrophobic blocks typically are polyesters, polyethers, or polyamino acids, such as poly([l]{.smallcaps}-aspartic acid), PLA, poly(ε-caprolactone) (PCL), and poly(propylene oxide) (PPO).[@b15-ijn-13-2921] The defining characteristic of PMs is the polymers' ability of spontaneous self-assembly into nanoscale aggregates. In aqueous solutions, the hydrophobic blocks self-associate into a semisolid core surrounded by the hydrophilic segments as a corona/shell. The hydrophilic shell provides steric stability and minimizes nonspecific uptake by the reticuloendothelial system (RES), resulting in the prolonged circulation time in the body.[@b16-ijn-13-2921],[@b17-ijn-13-2921] Given the fact that many anticancer drugs are water insoluble, the hydrophobic core of PMs provides a perfect place for drug loading. By this way, the insoluble drugs can be "solubilized". The critical micelle concentration (CMC) is the minimum concentration of copolymers required for micelle formation. At the concentration lower than CMC, the copolymers exist as monomers throughout the solution, while at the concentration around or above CMC, the polymer chains associate and the self-assemblies/micelles are formed. Most reported PMs showed quite low CMC in comparison with low-molecular-weight surfactant micelles.[@b17-ijn-13-2921]

In the early 1980s, Gros et al first reported PMs as drug delivery vehicles for cancer treatment.[@b18-ijn-13-2921] Since then, a great number of PMs have been developed to deliver various anticancer drugs and other bioactive molecules for cancer diagnosis and therapy. As drug carriers, the core--shell-structured PMs offer several advantages and unique properties for cancer-targeted drug delivery. First of all, as mentioned previously, PMs can load the water-insoluble drugs by physical entrapment or chemical conjugation, resulting in greatly increased drug solubility. As an example, 7-ethyl-10-hydroxy-camptothecin (SN-38), a highly effective anticancer agent, which acts as a DNA topoisomerase I inhibitor, cannot be administered intravenously due to its poor water solubility and high toxicity. By conjugation of the drug to PEG-poly(glutamic acid) (NK012), the solubility of the drug is significantly increased. As a result, the IC50 value of NK012 is deceased up to 5.8 times compared to that of free SN-38.[@b19-ijn-13-2921] In solid tumors, the tumor specificity of the nanodrug carriers considerably relies on the enhanced permeability and retention (EPR) effect, a passive targeting strategy.[@b20-ijn-13-2921],[@b21-ijn-13-2921] For passive targeting, nanoparticles have to circulate in the blood for a long period of time to ensure that sufficient drugs are delivered to the tumor tissue, in which their size plays a very important role. Nanoparticles smaller than 10 nm are easily eliminated through the renal glomeruli, whereas nanoparticles larger than 100 nm can be cleared from the bloodstream rapidly by the liver and spleen.[@b22-ijn-13-2921]--[@b24-ijn-13-2921] On the basis of this knowledge, PMs with a suitable size (10--100 nm) can avoid their quick clearance from the body, thus allowing for their accumulation in the tumor tissues via the EPR effect. In addition, the biocom-patible polymeric corona of PMs can suppress nonspecific interactions with biological components and lead to reduced recognition by the RES, prolonging the circulation time in the bloodstream. Nevertheless, the EPR effect of PMs may not always benefit the treatments particularly in the human clinical trials due to the heterogeneity and complexity of the tumor environment. Thus, PMs can be further modified with ligands for active targeting to increase their tumor selectivity and intracellular drug delivery but reduce their systemic toxicity and other adverse effects.[@b25-ijn-13-2921] Compared to nontargeted PMs, a number of studies have showed the superior results of the active-targeting PMs, such as improved cellular uptake, cytotoxicity, and tumor regression, making the active targeting strategy an important addition to the passive targeting PMs. All these advantages demonstrate PMs may be a promising and powerful drug platform for cancer therapeutic applications.

Stimuli-responsive PMs
======================

Despite the successful applications of PMs as anticancer drug carriers, some problems remain. For example, PMs are highly associated with premature drug release in the circulation and inadequate drug release upon accumulation in the targeted tissue.[@b26-ijn-13-2921] Ideally, the drug is retained in the PMs during circulation but is released after accumulation in the tumor interstitium. The premature drug release can be prevented by appropriate micelle stabilization or enhancement of drug interaction in the micelle core via specific bonding strengths like hydrogen bonds or cleavable covalent bonds. As to achieving tumor-targeted drug delivery and adequate release, a very effective way is the design of stimuli-responsive PMs. With the increasing knowledge of tumor biology, we know that tumor tissues possess a low pH in solid tumors with an even lower pH inside tumor cells, overexpressed specific enzymes, high levels of glutathione (GSH) in the cytoplasm, as well as a higher temperature compared with the normal tissues. These unique features can be utilized as internal triggers along with external stimuli such as magnetic field, ultrasound, and light to permit the destabilization of stimuli-responsive PMs and achieve temporally and spatially controlled drug delivery and release.[@b13-ijn-13-2921] The strategies for the development of stimuli-responsive PMs used in cancer therapy are reviewed individually below (typical stimuli-responsive PMs are summarized in [Table 2](#t2-ijn-13-2921){ref-type="table"}).

pH-responsive PMs
-----------------

The pH-responsive PMs have recently emerged as important nanocarriers for anticancer drug/imaging agent delivery.[@b27-ijn-13-2921]--[@b30-ijn-13-2921] As a result of enhanced metabolic rates and increased aerobic glycolysis, the microenvironment of most solid tumors is intrinsically acidic (pH 6.5--7.2), while the pH value in the blood and normal tissue is about 7.4. Moreover, an even lower acidic pH is found in endosomes (pH 6.5--5.5) and lysosomes (pH 4.5--5.0).[@b31-ijn-13-2921] Accordingly, the difference in pH has been widely exploited to achieve tumor site- or organelle-specific activation of pH-responsive PMs and on-demand drug release. The pH sensitivity of polymers mainly results from the protonation of ionizable groups or the degradation of pH-sensitive linkages. Therefore, one possible approach to impart pH sensitivity to PMs is to incorporate the ionizable groups into the micellar polymers to ionize at the tumor extracellular or intracellular acidic pH. After the micelle decomposition or destabilization, their payloads are released at the tumor tissues. For example, a pH-sensitive mixed micelle was prepared by Wu et al for cytosolic delivery of doxorubi-cin (DOX), which was composed of two block polymers, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine-PEG and pH-responsive poly(histidine) (PHis)-PEG.[@b32-ijn-13-2921] PHis is a commonly employed pH-sensitive polymer as the imidazole ring has an electron lone pair on the unsaturated nitrogen that endows PHis with an amphoteric nature by protonation--deprotonation. Such systems could not only stabilize the micelles at neutral and tumor extracellular pH (pH~e~) but also facilitate micelle's disintegration and then result in quick drug release in response to the low endocytic pH. Similarly, Hu et al utilized polysulfadimethoxine (PSDM) and PHis to construct a micellar system to realize sequential pH responsiveness at the tumor extracellular and endosomal pH.[@b33-ijn-13-2921] Cationic micelles were prepared from a block copolymer of PHis-poly(ethylene imine) (PEI), which was shielded by the negatively charged methoxy PEG (mPEG)-PSDM at pH 7.4 and deshielded at the tumor extracellular pH due to the pH-responsive sulfonamide group of PSDM. After endocytosis, PHis was protonated in the endosomal compartment, leading to dissociation of the micelle and destabilization of the endosomal membrane to promote the delivery of drugs to the cytosol. The in vivo results demonstrated that the PMs showed significant anticancer efficacy and deep penetration into tumor tissues.

Another common pH-sensitive strategy utilizes the degradation of pH-sensitive linkages at compartments with lower pH. In recent years, one major branch of our research focused on stimuli-responsive nanodrug delivery systems, and our group has made several attempts to construct pH-sensitive PMs for cancer therapy.[@b32-ijn-13-2921],[@b34-ijn-13-2921],[@b35-ijn-13-2921] In a study, a novel delivery system based on luteinizing hormone-releasing hormone (LHRH)-PEG-PHis-DOX/DOX-trans-activating transcriptional activator (TAT) acid-sensitive micelle was developed, as shown in [Figure 1](#f1-ijn-13-2921){ref-type="fig"}, which could dissociate and release DOX-TAT when responding to the tumor extracellular pH.[@b34-ijn-13-2921] Such systems could efficiently go across the cell membrane and reach the cytosol of the multidrug-resistant cancer cells, resulting in the remarkable antitumor efficacy and negligible systematic toxicity. Zhou et al developed an *N*-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-based micellar drug delivery system, in which the hydrophobic drug DOX and β-sitosterol were conjugated to the hydrophilic HPMA polymer backbone via a pH-sensitive hydrazone linker.[@b36-ijn-13-2921] The pH-responsive linker was stable at physiological pH but could be easily hydrolyzed at acidic pH. In the in vitro studies, the PMs could quickly collapse with 80% of the drug released at pH 5, the lyso/endosomal pH. In the in vivo studies, the PMs showed significantly higher anticancer effect.

As we know, the positively charged carriers could effectively interact with the negatively charged cell membrane by electrostatic attraction and trigger efficient cell internalization.[@b37-ijn-13-2921],[@b38-ijn-13-2921] However, for in vivo drug delivery, positively charged surface is not favorable due to nonspecific interactions and resultant short circulation half-life.[@b39-ijn-13-2921],[@b40-ijn-13-2921] Thus, strategies that make use of charge conversion or charge reversal are highly required and always in pursue for pH-sensitive drug delivery, in which PMs are usually neutral or negatively charged at physiological pH and are capable of converting their surface charge into positive one in response to the tumor extracellular pH. In our previous work, a dual pH-sensitive charge-reversing poly(β-[l]{.smallcaps}-malic acid) (PMLA)-based micellar nanocomplex (PMLA-PEI-DOX-TAT\@PEG-2,3-dimethylmaleic anhydride (DMMA)) was developed for effective tumor-targeted drug delivery, enhanced cellular uptake, and intracellular drug release, which is illustrated in [Figure 2](#f2-ijn-13-2921){ref-type="fig"}.[@b35-ijn-13-2921] The prepared micellar nanocomplex showed a negative surface charge at the physiological pH, while at the tumor extracellular environment, charge reversal of PEG-DMMA took place and the positively charged and TAT-exposed PMs were released, resulting in enhanced cellular internalization. Moreover, after endocytosis, the PMs showed pH-sensitive quick drug release at the endo/lysosomal pH because of the pH-sensitive linker.

Redox-responsive PMs
--------------------

Redox potential has been regarded as a viable biomarker to distinguish between the extracellular and intracellular environments, as well as between the tumor and normal tissues due to the difference in the GSH concentration. The concentration of GSH in cytoplasm (approximately 2--10 mM) could be 100--1,000 times higher than that in the extracellular environments (approximately 2--10 μM).[@b41-ijn-13-2921]--[@b43-ijn-13-2921] In comparison with healthy tissues, some tumor tissues are found to be highly reducing and hypoxic, with the intracellular GSH concentration being at least four times higher than that of the normal cells.[@b41-ijn-13-2921],[@b43-ijn-13-2921] In the past decade, a tremendous progress was made in the development of redox-responsive nanovehicles for targeted intracellular drug or gene delivery as the redox response is exceedingly fast and efficient in the presence of high concentration of GSH in the tumor or intracellular environments. In addition, unlike pH-sensitive nanocarriers that are usually designed to release drugs in the lyso/endosomal compartments, redox-responsive systems can disassemble and release drugs in the cytosol and cell nucleus. Disulfide bonds, prone to rapid cleavage by GSH, are commonly used to gain redox sensitivity. The chemical structure of disulfide-containing cross-linking agents is shown in [Figure 3](#f3-ijn-13-2921){ref-type="fig"}. Until now, a number of redox-responsive PMs have been designed by incorporating a disulfide bond either in the hydrophobic blocks or between the hydrophobic and hydrophilic segments.[@b44-ijn-13-2921]--[@b46-ijn-13-2921] Under the redox environment, these PMs can be reductively degradable or rapidly disassembled to release payloads.

Shi et al used four-arm PCL-PEG copolymers to develop a multifunctional star-shaped micellar system by combination of active targeting ability and redox-responsive behavior.[@b47-ijn-13-2921] The redox-responsive behavior was realized by connecting PCL and PEG via disulfide bonds, and active targeting ability was achieved by the introduction of folate (FA) ligands to the end groups of the hydrophilic segment, as shown in [Figure 4](#f4-ijn-13-2921){ref-type="fig"}. DOX was trapped into the micelles during the self-assembly of the star-shaped PCL-PEG copolymers. The prepared redox-responsive PMs could be specifically internalized by tumor cells through the FA receptor-mediated endocytosis, and the disulfide bonds could be immediately cleaved in response to the intracellular high level of GSH, resulting in quick DOX release. The same group reported another redox-responsive polyanhydride-based micelle for cancer therapy.[@b48-ijn-13-2921] The amphiphilic polyanhydride copolymer contained disulfide bonds between the hydrophilic and hydrophobic segments. Redox sensitivity of the micelles was demonstrated by the changes of the micellar size, morphology, and molecular weight. Particularly, an approximate zero-order in vitro drug (curcumin) release mode in a short time was observed in a reducing and acidic environment which was similar to that of the tumor cell, leading to significant in vitro and in vivo antitumor activities.

Enzyme-responsive PMs
---------------------

Enzymes play critical roles in many biological and metabolic processes inside the body due to their exceptional specificity and outstanding catalytic properties.[@b49-ijn-13-2921] The dysregulation of enzyme expression and activity has been observed in a variety of different pathological situations and is associated with many diseases. For example, the expression of several types of enzymes like proteases, peptidases, and lipases in solid tumors is often greater compared to their concentrations in normal tissues since high concentrations of these enzymes play a very important role in tumor cell growth, angiogenesis, invasion, and metastasis.[@b50-ijn-13-2921]--[@b52-ijn-13-2921] Dysregulated enzymes have been considered as biomarkers for diagnostics and prognostics in different types and stages of cancer, which are also emerging as promising biological triggers for targeted cancer therapy. Using enzymes as a trigger could provide a number of benefits as most enzymes catalyze chemical reactions under mild conditions (eg, low temperature and neutral pH value), however, many conventional nonenzymatic chemical reactions may not happen under such conditions. Moreover, enzymes possess highly exceptional selectivity for their substrates, thus allowing for specific, complicated, biologically inspired chemical reactions. Based on these principles, in the past few years, a wide variety of NDDSs have been developed as the enzyme-responsive systems for selective and efficient targeted drug delivery, including polymeric nanoparticles, liposomes, and inorganic nanoparticles.[@b49-ijn-13-2921],[@b53-ijn-13-2921]--[@b56-ijn-13-2921] The enzyme responsiveness can be rendered to the PMs for anticancer drug delivery by incorporating specific moieties in their main chain or side groups that can be selectively recognized and degraded by overexpressed enzymes in the extra/intracellular environment of the tumor, enabling tumor-targeted and spatiotemporal drug release with reduced unwanted side effects in normal tissues.

Matrix metalloproteinases (MMPs), a kind of extracellular matrix (ECM)-remodeling proteases, have been found highly associated with tumor invasion and metastasis.[@b50-ijn-13-2921],[@b51-ijn-13-2921] They are a family of zinc- and calcium-dependent endopeptidases that are responsible for the degradation and remodeling of the ECM and are relatively overexpressed in almost all tumors compared with normal tissues. Thus, MMPs can be employed to achieve enzyme-responsive site-specific drug release. Among them, MMP2 and MMP9 are the most widely explored enzymes for enzymatic drug delivery. For example, a unique tumor-targeted micellar drug delivery platform was reported by Zhu et al, which was prepared by self-assembly of the block copolymers of MMP2-sensitive PEG~2000~-PTX conjugate, transactivating transcriptional activator peptide-PEG~1000~-phosphoethanolamine (PE), and PEG~1000~-PE, acting as MMP2-sensitive functional polymer, cell-penetrating enhancer, and nanocarrier building block, respectively ([Figure 5](#f5-ijn-13-2921){ref-type="fig"}).[@b57-ijn-13-2921] The MMP2 sensitivity of PEG~2000~-peptide-PTX as well as the whole micelle formation was well character-ized. Compared to nonsensitive counterparts, like free PTX and conventional micelles, both in vitro and in vivo studies indicated that this novel design showed superior cell internalization, cytotoxicity, tumor targeting, and antitumor efficacy, which had great potential for effective intracellular delivery of drug into cancer cells. More recently, they designed another MMP2-sensitive multifunctional PM for tumor-specific co-delivery of siRNA and hydrophobic drugs.[@b58-ijn-13-2921] This micellar platform was constructed by an MMP2-sensitive copolymer (PEG-pp-PEI-PE) via self-assembly, which exhibited excellent stability, efficient siRNA condensation by PEI, PTX solubilization in the lipid core, and tumor targeting via both the EPR effect and MMP2 sensitivity.

Thermo-responsive PMs
---------------------

Temperature, which acts as either an internal or an external stimulus, is one of the most often investigated stimuli for drug delivery. Alteration of the temperature in specific tissues can either occur due to certain diseases (eg, tumor, inflammation, or infection) or be achieved by the application of an external heating source/device.[@b59-ijn-13-2921],[@b60-ijn-13-2921] In addition, the elevated temperature, or "hyperthermia", can also inflict additional damage to tumor cells, such as inhibition of DNA synthesis and repair, disruption of microtubules, and alteration of the receptor expression. Therefore, temperature/thermo-responsive drug delivery systems are among the most investigated stimuli-responsive strategies for cancer therapy.[@b61-ijn-13-2921]--[@b64-ijn-13-2921] The thermo-sensitive PMs comprise polymers with thermo-responsive blocks which undergo a sharp change of their physical properties in response to the change of temperature to destabilize the micelles and trigger drug release. Thermo-responsive polymers tend to undergo a phase transition at a certain temperature, known as lower critical solution temperature (LCST).[@b65-ijn-13-2921]--[@b67-ijn-13-2921] Below the LCST, the polymers are soluble in water by forming hydrogen bonds between water and the polymer chains, but become insoluble upon heating (above the LCST) due to disruption of hydrogen bonds. Moreover, the polymers can be modulated by introduction of hydrophobic or hydrophilic comonomers to obtain LCST values within a desired range (37°C--42°C), higher than normal body temperature but lower than the hyperthermia of tumors.

The most frequently used thermo-responsive polymer for the preparation of thermo-sensitive PMs is poly(*N*-isopropylacrylamide) (PNIPAAm) with an LCST of around 32°C, which is close to the physiological temperature of the human body.[@b68-ijn-13-2921]--[@b71-ijn-13-2921] The LCST of PNIPAAm can be optimized by random copolymerization with other monomers in order to get improved targeting and drug release. For example, Panja et al developed a smart thermo-responsive micelle from novel four-arm star-shaped block copolymers, namely PE-PCL-*b*-PNIPAAm-FA and PE-PCL-*b*-poly(*N*-vinylcaprolactam)-FA ([Figure 6](#f6-ijn-13-2921){ref-type="fig"}).[@b72-ijn-13-2921] A series of temperature-responsive polymers with specific LCST (ranging from 30°C to 39°C) were synthesized by tailoring the block length of the thermo-responsive segments. A high rate of DOX release (78.57% after 24 hours) at a temperature above LCST can be achieved due to the temperature-induced size reduction (57%) of the PMs. Moreover, the DOX release rate can also be tuned by on-demand administration of temperature. The in vivo study showed a drastic inhibition of the tumor volume by ∼83.9% without any significant systemic toxicity after administration of the prepared DOX-loaded PMs into the C6 glioma rat model. Similarly, Ahn et al used amphiphilic alginate-*g*-PNIPAAm to prepare a DOX-loaded and near-infrared (NIR) fluorescent dye-tagged PM for cancer imaging and therapy.[@b73-ijn-13-2921] Amino-PNIPAAm was conjugated to the alginate backbone by carbodiimide chemistry, the obtained alginate-*g*-PNIPAAm was dissolved in distilled water at room temperature, and self-assembled PMs were formed at 37°C. The in vitro result showed a sustained release of DOX from the PMs at 37°C. The resultant DOX-loaded alginate-*g*-PNIPAAm PMs exhibited excellent anticancer efficacy in a mouse model without any significant side effects, indicating high potential for the application of cancer imaging and therapy.

Magnetic field-responsive PMs
-----------------------------

Magnetic field-responsive PMs, typically incorporating the therapeutic payloads along with a magnetically active component, could be used not only for tumor targeting under an external magnetic field but also for quick drug release induced by the increased temperature caused by the alternating magnetic field, displaying great potential for cancer treatment.[@b74-ijn-13-2921],[@b75-ijn-13-2921] In addition, owning to its deep penetration, magnetic field represents a promising trigger for the in vivo application. Iron oxide nanoparticles with a size less than 10 nm, like magnetite (Fe~3~O~4~) and maghemite (Fe~2~O~3~), are most commonly used to impart the magnetic sensitivity.[@b76-ijn-13-2921]--[@b78-ijn-13-2921] They are also referred to as superparamagnetic iron oxide nanoparticles (SPIONs) due to their property of superparamagnetism and small sizes. They can be attracted by a magnetic field, but do not retain the residual magnetism upon removal of the field. Apart from magnetic drug targeting, SPIONs have also been widely used for other biomedical applications including magnetic resonance imaging (MRI), magnetic transfection, and magnetic hyperthermia.[@b79-ijn-13-2921] The magnetic hyperthermia is a good example. Under alternating magnetic field, SPIONs would lead to the increased local temperature, which could be utilized to either directly kill tumors or make them more susceptible in combination with chemotherapy. Therefore, magnetic-sensitive polymeric nanoparticles have been explored for remotely controlled drug release as well as a combination of cancer therapy and diagnosis.

Targeted delivery of therapeutics and diagnostics using nanotechnology holds great promise to minimize the side effects of conventional chemotherapy and enable specific and real-time detection of diseases. In this regard, Wei et al recently reported the development of a clickable and imageable nanovehicle assembled from multiblock polyurethanes for precise tumor theranosis.[@b80-ijn-13-2921] The soft segments of the polymers were based on detachable PEG and degradable PCL, and the hard segments were constructed from lysine and cystine derivatives bearing reduction-responsive disulfide linkages and click-active alkynyl moieties, allowing for post-conjugation of targeting ligands via a click chemistry ([Figure 7](#f7-ijn-13-2921){ref-type="fig"}). They found that the cleavage of PEG corona bearing a pH-sensitive benzoic-imine linkage could act as an on--off switch, which was capable of activating the clicked targeting ligands under extracellular acidic environment, followed by triggering the core degradation and payload release inside tumor cells. Furthermore, in combination with SPION entrapped in the micellar core, the prepared PMs exhibited excellent MRI contrast effects and T2 relaxation in vitro, as well as magnetically guided MRI and multimodal targeting of therapeutics to tumor precisely, resulting in significant inhibition of cancer with minimal side effect.

In a similar study, FA-bovine serum albumin (BSA)-functionalized SPION-loaded PMs were prepared by Li et al for tumor targeting and MRI.[@b81-ijn-13-2921] The SPION-loaded PMs were prepared by self-assembly of amphiphilic poly(2,2,3,4,4,4-hexafluorobutyl methacrylate-*co*-methacryloxyethyl trimethyl ammonium chloride)-*g*-methoxy PEG monomethacrylate (poly(HFMA-*co*-MOTAC)-*g*-PEGMA) copolymers and oleic acid-modified Fe~3~O~4~ nanoparticles, and then functionalized with FA-BSA by electrostatic interaction. In vivo MRI conducted on the nude mice bearing the Bel-7402 xenografts after bolus intravenous administration showed excellent tumor targeting and MRI capabilities, especially at 24 hours post-injection. A multifunctional theranostic micellar drug delivery system utilizing cationic poly(2-(dimethylamino)ethyl methacrylate) (PDMA)-*b*-PCL micelles was developed for the delivery of various agents, including SN-38, ultrasmall SPIONs, and siRNA that targets human vascular endothelial growth factor (VEGF).[@b82-ijn-13-2921] The prepared PMs could passively target tumor regions and synergistically facilitate VEGF silencing and chemotherapy, as well as acted as a negative MRI contrast agent in T2-weighted imaging, indicating a powerful tool for the cancer diagnosis and tracking of the therapeutic outcomes.

Ultrasound-responsive PMs
-------------------------

Due to the ease of administration, low cost, and deep penetration, ultrasound has been widely used in diagnostic and therapeutic applications for many years, and has been proven to be an efficient noninvasive approach for the diagnosis and treatment of a wide range of health problems such as osteoporosis and cardiovascular diseases.[@b83-ijn-13-2921] Additionally, ultrasound has been extensively explored as a trigger for spatiotemporally controlled release of active agents encapsulated in nanopreparations at the desired site, thus reducing unwanted side effects. In the past years, a number of NDDSs with ultrasound-triggered release, including nanocapsules,[@b84-ijn-13-2921]--[@b86-ijn-13-2921] nanoemulsions,[@b87-ijn-13-2921],[@b88-ijn-13-2921] liposomes,[@b89-ijn-13-2921],[@b90-ijn-13-2921] and PMs,[@b91-ijn-13-2921],[@b92-ijn-13-2921] have been reported. Ultrasound waves could produce thermal (by absorption of energy) and nonthermal/mechanical effects by the cavitation, resulting in the desta-bilization of nanopreparations and resultant drug release. In addition, ultrasound can also increase the permeability of biological barriers, such as cell membrane and blood--brain barrier, through the formation of cavitation bubbles and generated heat, leading to enhanced cellular uptake of the drugs.[@b93-ijn-13-2921] Ultrasound-responsive PMs have shown increased drug release upon exposure to ultrasound by the physical/chemical disruption of the micelles, representing an attractive drug delivery and release strategy. To date, the most extensively studied micelles for ultrasound-triggered drug release are based on Pluronic copolymers that are composed of a ternary copolymer of poly(ethylene oxide) (PEO) and PPO (PEO-PPO-PEO).[@b94-ijn-13-2921],[@b95-ijn-13-2921]

Recently, Wu et al developed Pluronic P123/F127 PMs encapsulating curcumin that could be permeabilized directly by focused ultrasound, leading to ultrasound-triggered drug release.[@b96-ijn-13-2921] Compared to free curcumin, curcumin-loaded P123/F127 mixed micelles showed longer circulating time and increased cellular uptake. With the assistance of the focused ultrasound, such micellar system exhibited tumor-targeted deposition in a time-dependent manner following systemic administration, which was caused by the enhanced permeabilization of tumor regions and increased penetration of PMs in irradiated tumor cells under ultrasound sonoporation. Additionally, the mixed micelles could be regulated by ultrasound irradiation. The in vivo site-specific drug release was demonstrated in dual-tumor models, which showed spatiotemporal release of the entrapped drugs following intratumoral injection, resulting in significant inhibition of the tumor growth by approximately 6.5-fold more than that of the PMs without ultrasound irradiation. In another interesting work, Liang et al synthesized a metal--supramolecular diblock copolymer (poly(propylene glycol)-PEG) with a mechano-labile bis(terpyridine)--Cu(II) complex linkage in the junction point, which could self-assemble into the spherical PMs in aqueous solution.[@b97-ijn-13-2921] They found that the weak Cu(II)--terpyridine dynamic bond in the copolymer chain was able to be cleaved under the high-intensity focused ultrasound, leading to the disruption of the copolymer micelles and the release of the loaded cargo.

Light-responsive PMs
--------------------

Among various trigger signals used in biomedical applications, light, including UV, visible, and infrared/NIR light, represents an attractive external stimulus owing to its noninvasive nature, the possibility of remote control, and high spatiotemporal resolution.[@b98-ijn-13-2921]--[@b101-ijn-13-2921] The use of NIR light is of particular interest due to its deep tissue penetration (up to about 10 cm in human body) without significant tissue damage, while UV light cannot penetrate deeply into the body as a result of absorption by the skin, blood, and tissues.[@b102-ijn-13-2921] In addition, light-induced reactions can be regulated for various applications by adjusting the light parameters like wavelength, intensity, and exposure time. Because of these advantages, a large number of light-responsive NDDSs have been developed to achieve on-demand drug release for cancer treatment. Among them, PMs and liposomes are the most commonly studied ones. The light-responsive PMs are typically obtained by incorporation and/or conjugation of chromophores, such as azobenzene, pyrene, cinnamoyl, spirobenzopyran, or nitrobenzyl groups, in/to the polymeric structure.[@b103-ijn-13-2921]--[@b105-ijn-13-2921] Upon illumination, the PMs' nanostructure changes and the micelles dissociate, thus releasing the payloads. Due to the ability of reversible UV--visible pho-toisomerization, azobenzene and its derivatives are one of the most widely studied light-responsive chromophores, which can undergo a *trans*-to-*cis* photoisomerization of nitrogen double bond upon the UV irradiation, while this conversion can be reconverted to the *trans* isomer under the visible light. However, some other chromophores like 2-diazo-1,2-napthoquinone (DNQ) undergo light-responsive irreversible cleavage, converting hydrophobic molecules into hydrophilic ones.[@b106-ijn-13-2921] Accordingly, light-responsive PMs are categorized into two types based on the above mechanisms of destabilization, including reversible structural change and irreversible photo-cleavage.

Poelma et al presented one-photon visible light-responsive PMs using the reversible structural change strategy for efficient, on-demand delivery of small molecules.[@b107-ijn-13-2921] They developed the donor--acceptor Stenhouse adducts (DASAs) which could undergo a hydrophobic-to-hydrophilic polarity change triggered by visible light between 530 and 570 nm.[@b108-ijn-13-2921] Compared to two-photon processes, molecules with one-photon absorption showed more desirable wavelengths and were more efficient, with the photoisomerization of DASA systems being triggered by low intensities of light (∼1 mW cm^−2^). In this study, the DASA building blocks were used as photochromic units in the construction of PMs, allowing for the light-triggered release of small molecules to cells by the structural disassembly of micelles using one-photon visible light. Spiropyran (SP), a well-known photochromic molecule, was exploited by Son et al to initiate the ring-opening multibranching polymerization of glycidol to afford a series of hyper-branched polyglycerol (SP-hb-PG) micelles.[@b109-ijn-13-2921] The micelle assembly and disassembly could be induced by an external light source owing to the reversible photoisomerization of hydrophobic SP to hydrophilic merocyanine corresponding to the color change from colorless to pink. The assembly and disassembly of SP-hb-PG micelles were confirmed by a series of experiments, involving transmission electron microscopy (TEM), atomic force microscopy, UV--visible spectroscopy, and dynamic light scattering (DLS).

In addition to the reversible photoisomerization, the light-induced cleavage of chemical bonds has also been widely used in light-responsive PMs. Saravanakumar et al reported a biocompatible amphiphilic block copolymer (^1^O~2~-PEG-*b*-PCL) formed PMs bearing a singlet oxygen (^1^O~2~)-sensitive vinyldithioether cleavable linker at the core--shell junction, which could undergo ^1^O~2~-mediated photocleavage in the presence of visible light, leading to light-responsive release of ^1^O~2~ and anticancer drugs for enhanced photodynamic therapy ([Figure 8](#f8-ijn-13-2921){ref-type="fig"}).[@b110-ijn-13-2921] The double bond of the vinyldithioether linker can readily react with ^1^O~2~ to form a dioxetane intermediate, which is unstable and spontaneously cleaved. Unlike other conventional photo-responsive micelles that demand direct absorption of UV light, the prepared PMs utilized the ^1^O~2~ generated by visible light during photodynamic therapy as a trigger to disassemble and release a co-loaded drug in the tumor cell for effective therapy. In another study, Sun et al reported the preparation of an amphiphilic dendritic polymer of PEO-D3DNQ for both UV- and NIR-triggered drug release.[@b111-ijn-13-2921] In this work, PEO-D3DNQ was prepared by click conjugation between DNQ-decorated poly(amido amine) dendron D3 (generation 3) and azide-terminated PEO (PEO-N3, molecular weights of 2 and 5 kDa). As character-ized by time-resolved UV--visible spectroscopy, DLS, and TEM, the obtained micelles exhibited both UV and NIR sensitivity in phosphate-buffered saline (PBS). It was found that the characteristic absorption intensity of DNQ progressively decreased and then leveled off within 8 minutes under UV365 nm irradiation, suggesting the completion of the Wolff rearrangement of DNQ, while under 808 nm NIR irradiation, it took a longer time of 40--60 minutes to complete the Wolff rearrangement of DNQ. After 30 minutes of 808 nm irradiation, most of the micelles could be disrupted and the apparent drug-release rate showed a nearly eightfold increase, presenting an NIR-triggered drug-release profile.

Multi-responsive PMs
--------------------

Multi-stimuli-responsive PMs that are sensitive to two or more stimuli are emerging and have shown great potential for cancer-targeted drug delivery and therapy. By combining multiple stimuli sensitivities into one PM system, a precisely controlled drug delivery and release can be achieved, resulting in superior in vitro and/or in vivo anticancer activity. The combined sensitivities to different stimuli can take place either simultaneously or in a sequential way.

### Dual pH/redox-responsive PMs

Dual pH/redox-responsive PMs have been developed, as both stimuli are naturally present in the cancer microenvironment. Recently, Alex et al prepared a dual redox/pH-responsive PM for co-delivery of DOX and polo-like kinase 1 siRNA.[@b112-ijn-13-2921] Cationic structures including histidine and arginine were first grafted to the poly(styrene-altmaleic anhydride) through dis-ulfide linkages, and then short PEG chains were incorporated to impart stealth nature and self-assembly ability. Besides, in order to make them stabile in physiological conditions, drug-loaded PMs were noncovalently coated with BSA. The dual-stimuli-sensitive nature of the PMs significantly increased their drug release at low pH and 10 mM GSH which mimicked the endosomal pH and GSH-rich microen-vironment of cancer cells. Both in vitro and in vivo results showed synergistic effects of DOX and siRNA in inhibiting tumor cell proliferation.

### Dual pH/thermo-responsive PMs

Among various dual-stimuli-responsive PMs developed for cancer therapy, pH and temperature are the most commonly studied combination because of the tumor's acidity and relatively higher local temperature or easily applied external heat sources. Hong et al conjugated PHis to poly(lactic-*co*-glycolic acid) (PLGA)-PEG-PLGA to form PHis-PLGA-PEG-PLGA-PHis copolymers, by which a thermo- and pH-responsive PM was developed.[@b113-ijn-13-2921] The temperature- and pH-induced structural changes of the PMs were characterized by alteration in particle size, pyrene fluorescence intensity, and ^1^H NMR spectra in D~2~O. Additionally, the in vitro drug release, cyto-toxicity, and intracellular localization further confirmed the temperature- and pH-responsive properties of the copolymer micelles. In another study, Chen et al prepared an optimized, biodegradable, dual temperature/pH-responsive PM system for enhanced tumor accumulation, in which the hydrophobic segment of dual-responsive copolymer was composed of poly(*N*-(2-hydroxypropyl) methacrylamide dilactate)-*co*-(*N*-(2-hydroxypropyl) methacrylamide-*co*-histidine).[@b114-ijn-13-2921] The poly(*N*-(2-hydroxypropyl) methacrylamide dilactate) had a thermo-reversible LCST suitable for the targeted delivery of a variety of cargos, and histidine was pH sensitive and widely used in polymeric drug delivery systems.

### Dual redox/magnetic-responsive PMs

The redox-responsive magnetic nanoparticles such as SPIONs have been developed to combine redox-responsive drug release with magnetic targeting and imaging. Recently, Tang et al developed redox-responsive star-shaped magnetic micelles with active-targeted and magnetic-guided functions for cancer therapy.[@b115-ijn-13-2921] The magnetic star-shaped micelles were formed by self-assembly of four-arm PEG-PCL copolymers with disulfide bonds as intermediate linkers. DOX and magnetic iron oxide nanoparticles (Fe~3~O~4~) were simultaneously encapsulated into the hydrophobic cores of the micelles. The active targeting was rendered by the conjugation of phenyl-boronic acid ligands that showed high affinity and selectivity to the tumor-overexpressed antigen salic acid. The resultant magnetic PMs enhanced the antitumor efficacy under magnetic field but decreased the adverse effects.

### Dual redox/enzyme-responsive PMs

In a recent study, Zhang et al developed dual enzyme/redox-responsive PMs with active targeting abilities to achieve rapid intracellular drug release.[@b116-ijn-13-2921] In order to overcome the drugs' poor solubility and low stability, camp-tothecin (CPT) was chemically conjugated to mPEG via a redox-responsive linker to form polymeric prodrugs. The enzyme-responsive behavior was achieved by introduction of the azo bonds as the linker between the hydrophobic poly-caprolactone and hydrophilic PEG segments. The azo bonds can be selectively cleaved by oxidation--reduction enzyme (azoreductase) in the presence of the coenzyme-reduced nicotinamide adenine dinucleotide phosphate. In addition, PBA was conjugated to the end of PEG to realize active tumor targeting and cellular uptake via receptor-mediated endocytosis. In the cytoplasm, CPT could be rapidly released through the dual triggers of enzyme and redox responsiveness and effectively inhibited the tumor proliferation and decreased the side effects.

### Triple pH/thermo/redox-responsive PMs

In addition to dual-responsive PMs, triple-responsive systems are also attracting increasing interest. Huang et al reported novel triple thermo/pH/reduction-sensitive PMs based on a block copolymer p(poly(ethylene glycol) methyl meth-acrylate-*co*-(*tert*-butyloxycarbonylaminoethyldithioethyl methacrylamide)-*co*-vinylimidazole) (p(PEG-MEMA-*co*-Boc-Cyst-MMAm-*co*-VI))-b-PEG (PPBV) for intracellular drug delivery.[@b117-ijn-13-2921] The pH/temperature-responsive behavior of such PMs was observed by both DLS and UV--vis absorbance. When the solution was heated above 21°C, the size of PPBV in PBS (pH 7.4) increased rapidly from 25 to 56 nm. Besides, the size--temperature curves for PPBV in aqueous solution moved toward higher temperatures with decreasing pH from 7.4 to 6.0. The PTX-loaded micelles showed slow drug release in PBS but rapid release after exposure to a weakly acidic pH or reductive environment, indicating the pH- and reduction-sensitive behavior of PPBV. The obtained PMs showed higher cytotoxicity against HepG2 cells due to the increased intracellular PTX concentration, which therefore may serve as promising carriers for cytostatic drugs.

Conclusion
==========

A large number of preclinical studies on multifunctional PMs have been published, which showed that PMs-based drug delivery systems are promising to be an effective nanomedicine platform for drug delivery and cancer therapy, resulting in enhanced therapeutic index and reduced systemic side effects compared to traditional anticancer drugs. PMs are one of the nanocarriers that can selectively target drug to the tumor though the EPR effect. The small size along with the suitable surface properties such as the hydrophilic PEG corona could prevent the PMs from rapid clearance from the body, allowing for prolonged circulation time and efficient tumor accumulation. Additionally, as most of the anticancer drugs are poorly water-soluble, PMs may be a perfect way for drug solubilization as well as delivery. Moreover, PMs can be further modified with tumor targeting ligands to increase the drug's tumor selectivity and enhance intracellular drug delivery. To date, about nine drug-loaded PMs have been investigated in clinical trials, of which Genexol-PM was approved in 2007 in Korea and marketed in Europe for treating breast cancer and small-cell lung cancer. However, the clinical translation and desired therapeutic effects of PMs are still far from satisfactory. The drug-loaded PMs currently investigated in the clinical trials mostly rely on the passive tumor targeting via the EPR effect; however, their targeting effect in human sometimes is not as pronounced as that obtained in the simple cell and animal models due to the complexity of the tumor and human body. Besides, the premature drug release in the bloodstream and inadequate drug release in the tumor may also account for the inferior therapeutic effects in human patients. Thus, in order to ensure the success of PMs, further modification of micelles is required regarding the drug loading and release, blood circulation, tumor targeting, cellular uptake, and intracellular drug release.

Numerous stimuli-responsive PMs have been developed to deliver anticancer drug in response to a variety of extra/intracellular stimuli or external triggers, including pH, redox potential, enzymes, temperature, light, ultrasound, and magnetic field, which showed the improved performance in addressing the above-mentioned concerns. Despite the impressive process has been achieved in the design and application of stimuli-responsive PMs for cancer therapy, many challenges and crucial issues still remain to be addressed. First, it is crucial to understand how PMs interact with the biological components. Upon administration, PMs encounter a variety of biological molecules, cells, and tissues/organs. The surface of PMs would be immediately covered with biological molecules such as serum proteins which play an important role in determining the subsequent biodistribution and cellular responses of PMs. Second, off-target effects or insufficient stimuli sensitivity may happen due to the nonspecific distribution of the stimuli, especially internal stimuli. For example, low pH, high concentration of GSH, or upregulation of certain enzymes can also be found in some normal cells or nontumoral tissues. Besides, the heterogeneity of the patients and tumors and the tumor type and stage greatly influence the status of the internal stimuli. Thus, the stimuli sensitivity of PMs should be well studied. Third, the complicated design and difficulties in the scale-up of stimuli-responsive PMs are likely to hamper their clinical translation, which is one major reason why a number of stimuli-responsive PMs have been reported, whereas only a few of them could enter the clinical stage.

Summing up, we reviewed the recent progress of stimuli-responsive PMs for cancer therapy and highlighted the representative examples regarding the stimuli-responsive temporal and spatial drug delivery and release. The potential and progress of stimuli-responsive PMs have been clearly shown in previous studies. In the near future, we believe that the stimuli-responsive PMs would become an important component of clinical cancer therapy.
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![(**A**) Delivery strategy of LHRH-PEG-PHis-DOX/DOX-TAT micelles. (**B**) Images of the tumors on day 14 after the inoculation of A2780/DOX^R^ tumor cells in the mice and in vivo antitumor efficacy.\
**Notes:** Reprinted from Yang T, Li F, Zhang H, et al. Multifunctional pH-sensitive micelles for tumor-specific uptake and cellular delivery. *Polym Chem*. 2015;6(8):1373--1382.[@b34-ijn-13-2921] With permission from the Royal Society of Chemistry. Copyright 2014 Royal Society of Chemistry.\
**Abbreviations:** LHRH, luteinizing hormone-releasing hormone; PEG, poly(ethylene glycol); PHis, poly(histidine); DOX, doxorubicin; TAT, trans-activating transcriptional activator.](ijn-13-2921Fig1){#f1-ijn-13-2921}

![(**A**) Preparation of nanocomplex PMLA-PEI-DOX-TAT\@PEG-DMMA. (**B**) Schematic illustration of the dual pH-sensitive DOX-loading nanocomplex with the charge-conversional function for effective tumor-targeted drug delivery, enhanced cellular uptake, and intracellular drug release.\
**Notes:** Reprinted from Zhou Q, Hou Y, Zhang L, et al. Dual-pH sensitive charge-reversal nanocomplex for tumor-targeted drug delivery with enhanced anticancer activity. *Theranostics*. 2017;7(7):1806--1819.[@b35-ijn-13-2921] Creative Commons Attribution (CC BY-NC) license, available from: <https://creativecommons.org/licenses/by-nc/4.0/>\
**Abbreviations:** PMLA, poly(β-[l]{.smallcaps}-malic acid); PEI, poly(ethylene imine); DOX, doxorubicin; TAT, trans-activating transcriptional activator; PEG, poly(ethylene glycol); DMMA, 2,3-dimethylmaleic anhydride.](ijn-13-2921Fig2){#f2-ijn-13-2921}

![Chemical structures of disulfide-containing redox-sensitive linkers.\
**Abbreviations:** SAND, sulfosuccinimidyl 2-(m-azido-o-nitrobenzamido)-ethyl-1,3′-dithio propionate; SAED, sulfosuccinimidyl-2-(7-amino-4-methylcoumarin-3-acetamido)-ethyl-1,3-dithiopropionate; LC-SPDP, succinimidyl 6-(3(2-pyridyldithio)propionamido)hexanoate; LC-SMPT, 4-succinimidyloxycarbonyl-α-methyl-α(2-pyridyldithio)toluene; SFAD, sulfosuccinimidyl-(perfluoroazidobenzamido)-ethyl-1,3′-dithiopropionate.](ijn-13-2921Fig3){#f3-ijn-13-2921}

![Schematic illustration of DOX-loaded star-shaped micelles based on FA-functionalized and redox-responsive star copolymer (star-PCL-ss-PEG-FA) for FR-mediated endocytosis and GSH-triggered intracellular drug release.\
**Notes:** Reprinted from Shi C, Guo X, Qu Q, Tang Z, Wang Y, Zhou S. Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. *Biomaterials*. 2014;35(30):8711--8722.[@b47-ijn-13-2921] With permission from Elsevier. Copyright 2014 Elsevier.\
**Abbreviations:** DOX, doxorubicin; FA, folate; PCL, poly(ε-caprolactone); FR, folate receptor; GSH, glutathione; PEG, poly(ethylene glycol).](ijn-13-2921Fig4){#f4-ijn-13-2921}

![(**A**) Drug delivery strategy. (**B**) Enzymatic cleavage. To determine the digestion of PEG~2000~-peptide-PTX (left) and its nanopreparation (right), the samples were treated with 5 ng/μL MMP2 followed by TLC and Dragendorff's reagent staining. (**C**) Cellular uptake in A549 cell monolayer. Cells were treated with NBD-PE-labeled formulations (green) for 2 hours before measurement. (a) PEG1000-PE, (b) TATp-PEG1000-PE, (c and d) TATp-PEG1000-PE/PEG2000-peptide-PTX. For FACS (left), cells were trypsinized and collected. For confocal microscopy (right), cells were fixed and stained with Hoechst 33342. (**D**) Cytotoxicity of the nanopreparations in A549 cell monolayer. Cells were treated with moderate-to-low doses of PTX formulations for 72 hours before CellTiter-Blue Cell Viability Assay. (**E**) Tumor growth inhibition (% of the starting tumor volume). (a) HBSS, (b) TATp-PEG1000-PE/PEG2000-peptide-PTX uncleavable, (c) PEG2000-PE/PTX, (d) Free PTX, (e) TATp-PEG1000-PE/PEG2000-peptide-PTX. \**P*\<0.05 compared with other groups.\
**Notes:** Reprinted from Zhu L, Wang T, Perche F, Taigind A, Torchilin VP. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. *Proc Natl Acad Sci USA*. 2013;110(42):17047--17052.[@b57-ijn-13-2921] With permission from the National Academy of Sciences. Copyright 2013 National Academy of Sciences.\
**Abbreviations:** PEG, poly(ethylene glycol); PTX, paclitaxel; MMP2, matrix metalloproteinase 2; TLC, thin-layer chromatography; NBD, Nitro-2-1,3-BenzoxaDiazol-4-yl; PE, phosphoethanolamine; FACS, fluorescence-activated cell sorting; TATp, transactivating transcriptional activator peptide; GPLG, Gly-Pro-Leu-Gly; IAGQ, Ile-Ala-Gly-Gln.](ijn-13-2921Fig5){#f5-ijn-13-2921}

![(**A**) Schematic presentation of temperature-induced shrinkage of micelles followed by drug release. (**B**) Fluorescence microscopic image of DOX-loaded FA-PM-treated C6 glioma cell line over a time span of 1--4 hours. The nuclei were stained with DAPI. (**C**) Tumor volume of the rat. (**D**) Variation of tumor volume with time. (**E**) Microscopic image of in vivo accumulation of control, free DOX, DOX-loaded PMs, and DOX-loaded FA-PMs into the tumor tissue.\
**Notes:** Fluorescence microscopies: red for DOX; blue for DAPI. Reprinted with permission from Panja S, Dey G, Bharti R, et al. Tailor-made temperature-sensitive micelle for targeted and on-demand release of anticancer drugs. *ACS Appl Mater Interfaces*. 2016;8(19):12063--12074.[@b72-ijn-13-2921] Copyright 2016 American Chemical Society.\
**Abbreviations:** DOX, doxorubicin; FA, folate; PM, polymeric micelle; DAPI, 4′,6-diamidino-2-phenylindole; LCST, lower critical solution temperature.](ijn-13-2921Fig6){#f6-ijn-13-2921}

![Design of clickable and imageable multiblock polymer micelles. (**A**) Schematic chemical structure and (**B**) molecular architecture of clickable MPUs. The waved lines in (**A**) represent PCL soft segments. (**C**) Self-assembly of MPU micelles and post-conjugation of FA via click chemistry. (**D**) Schematic illustration of FA residues on the interface of polymer micelles. (**E**) Illustration of magnetic-guided and PEG-switched targeting and release properties of MPU nanocarriers.\
**Note:** Reprinted from Wei J, Shuai X, Wang R, et al. Clickable and imageable multiblock polymer micelles with magnetically guided and PEG-switched targeting and release property for precise tumor theranosis. *Biomaterials*. 2017;145:138--153.[@b80-ijn-13-2921] With permission from Elsevier. Copyright 2017 Elsevier.\
**Abbreviations:** 1MPU, multiblock polyurethane; PCL, poly(ε-caprolactone); FA, folate; PEG, poly(ethylene glycol); BPEG, benzoic-imine linkage bearing PEG; Cys-PA, L-cystine-propargylamine; AzFA, azido modified FA; SSPHPU, BPEG-(PCL- Cys-PA)-BPEG; SPIONs, superparamagnetic iron oxide nanoparticles; GSH, glutathione.](ijn-13-2921Fig7){#f7-ijn-13-2921}

![Schematic illustration of (**A**) the formation of Ce6 and DOX co-loaded micelles (^1^O~2~-PM-Ce6-DOX), (**B**) cellular uptake and visible light-triggered ^1^O~2~-mediated intracellular co-delivery of Ce6 and DOX for combination chemo- and photodynamic therapy, and (**C**) chemical structure of the ^1^O~2~-PEG-*b*-PCL copolymer.\
**Notes:** Reprinted from Saravanakumar G, Lee J, Kim J, Kim WJ. Visible light-induced singlet oxygen-mediated intracellular disassembly of polymeric micelles co-loaded with a photosensitizer and an anticancer drug for enhanced photodynamic therapy. *Chem Commun (Camb)*. 2015;51(49):9995--9998.[@b110-ijn-13-2921] Creative Commons Attribution 3.0 Unported License. Published by the Royal Society of Chemistry.\
**Abbreviations:** Ce6, chlorin e6; DOX, doxorubicin; PM, polymeric micelle; PEG, poly(ethylene glycol); PCL, poly(ε-caprolactone).](ijn-13-2921Fig8){#f8-ijn-13-2921}

###### 

Current clinical trials of anticancer drug-loaded polymer micelles

  Name                                                        Block copolymer   Drug                                    Indications                             Clinical status   References
  ----------------------------------------------------------- ----------------- --------------------------------------- --------------------------------------- ----------------- -------------
  Genexol^®^-PM                                               PEG-PLA           PTX                                     Recurrent breast cancer                 Phase IV          NCT00912639
  Breast cancer                                               Phase III         NCT00876486                                                                                       
  Ovarian cancer                                              Phase II          NCT00877253, NCT00886717, NCT01276548                                                             
  Non-small-cell lung cancer                                  Phase II          NCT01023347, NCT01770795                                                                          
  Bladder and ureter cancer                                   Phase II          NCT01426126                                                                                       
  Pancreatic cancer                                           Phase II          NCT00111904                                                                                       
  Metastatic breast cancer                                    Phase II          NCT01784120                                                                                       
  Recurrent/metastatic adenocarcinoma of the pancreas         Phase II          NCT02739633                                                                                       
  Hepatocellular carcinoma                                    Phase II          NCT03008512                                                                                       
  Locally advanced head and neck squamous cell carcinoma      Phase II          NCT01689194                                                                                       
  Gynecologic cancer                                          Phase I           NCT02739529                                                                                       
  Ovarian cancer                                              Phase I           NCT00877253                                                                                       
  Pancreatic cancer                                           Phase I           NCT00882973                                                                                       
  NK105                                                       PEG-PAPB          PTX                                     Breast cancer                           Phase III         NCT01644890
  NC-6004                                                     PEG-PGlu          DDP                                     Head and neck neoplasms                 Phase I           NCT02817113
  Locally advanced and metastatic pancreatic cancer           Phase I/II        NCT00910741                                                                                       
  Squamous cell carcinoma of the head and neck                Phase I/II        NCT03109158                                                                                       
  Solid tumors                                                Phase I/II        NCT02240238                                                                                       
  Pancreatic cancer                                           Phase III         NCT02043288                                                                                       
  NK012                                                       PEG-PGlu          SN-38                                   Refractory solid tumors                 Phase I           NCT00542958
  Metastatic colorectal cancer                                Phase I           NCT01238939                                                                                       
  Metastatic triple-negative breast cancer                    Phase I           NCT01238952                                                                                       
  Small-cell lung cancer                                      Phase II          NCT00951613                                                                                       
  Triple-negative breast cancer                               Phase II          NCT00951054                                                                                       
  SP1049C                                                     PEG-PPO-PEG       DOX                                     Advanced adenocarcinoma                 Phase III         118--120
  BIND-014                                                    PEG-PLA           Docetaxel                               Advanced or metastatic cancer           Phase I           NCT01300533
  KRAS-positive or squamous cell non-small-cell lung cancer   Phase II          NCT02283320                                                                                       
  Non-small-cell lung cancer                                  Phase II          NCT01792479                                                                                       
  Metastatic castration-resistant prostate cancer             Phase II          NCT01812746                                                                                       
  NC-4016                                                     PEG-PGlu          OXA                                     Advanced solid tumor or lymphoma        Phase I           NCT03168035
  Nanoxel^®^M                                                 PEG-PLA           Docetaxel                               Head and neck squamous cell carcinoma   Phase II          NCT02639858
  Non-muscle-invasive bladder cancer                          Phase III         NCT02982395                                                                                       
  NK911                                                       PEG-PAPB          DOX                                     Various solid tumors                    Phase II          121,122

**Abbreviations:** PM, polymeric micelle; PEG, poly(ethylene glycol); PLA, poly([d]{.smallcaps},[l]{.smallcaps}-lactide); PTX, paclitaxel; PAPB, polyaspartate modified with 4-phenyl-butanol; PGlu, poly(glutamic acid); DDP, cisplatin; SN-38, 7-ethyl-10-hydroxy-camptothecin; PPO, poly(propylene oxide); DOX, doxorubicin; OXA, oxaliplatin.

###### 

Examples of stimuli-responsive polymeric micelles for cancer therapy

  Stimuli type                                             Acting stimulus                       Assembly units                                                              Cargoes                                                                                             Mechanisms/characteristics                                                         Achieved properties                                                References
  -------------------------------------------------------- ------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------ ---------------------
  Internal                                                 pH                                    PHis-*b*-sbPEI/mPEG-*b*-PSDM                                                PTX                                                                                                 Protonation of PSDM and PHis blocks                                                Triggered cationic charge shielding/deshielding and drug release   [@b33-ijn-13-2921]
  PEG-PHis PEG-PLA-DTPA-Gd                                 MRI contrast agents (CR-CAs)          Protonation of the imidazole groups of PHis blocks                          Enhanced MRI signals                                                                                [@b123-ijn-13-2921]                                                                                                                                   
  PEG-*b*-PDPA with TPGS                                   DOX                                   Protonation of the diisopropyl-substituted tertiary amino groups            Triggered dissociation and drug release                                                             [@b124-ijn-13-2921]                                                                                                                                   
  PEG-HPAH                                                 DOX and DTX                           Acylhydrazone bond cleavage                                                 Triggered drug release                                                                              [@b125-ijn-13-2921]                                                                                                                                   
  CTPP-PEG-CSOSA                                           Cela                                  High solubility of weakly acidic drug Cela in the alkaline pH environment   Mitochondrial fast drug release                                                                     [@b126-ijn-13-2921]                                                                                                                                   
  Redox                                                    mPEG-ss-CPP-SA                        Curcumin                                                                    Bond cleavage aggregation                                                                           Triggered drug release                                                             [@b127-ijn-13-2921]                                                
  HA-ss-(OA-g-bPEI)                                        PTX and si-AURKA                      Bond cleavage aggregation                                                   Triggered drug release                                                                              [@b128-ijn-13-2921]                                                                                                                                   
  PEG-PPE                                                  DOX                                   Bond cleavage aggregation                                                   Triggered drug release                                                                              [@b129-ijn-13-2921]                                                                                                                                   
  Four-arm PCL-PEG                                         DOX                                   Bond cleavage aggregation                                                   Triggered drug release                                                                              [@b47-ijn-13-2921]                                                                                                                                    
  Enzyme                                                   Biotin-PEG-*b*-PLL(Mal)-peptide-DOX   DOX                                                                         MMP2 selective cleavage                                                                             Triggered drug release                                                             [@b130-ijn-13-2921]                                                
  PhAc-FFAGLDD                                             DOX                                   MMP9 selective cleavage                                                     Triggered slow drug release                                                                         [@b131-ijn-13-2921]                                                                                                                                   
  mPEG-PA                                                  Curcumin                              Lipase-triggered hydrolysis of the ester linkage                            Triggered drug release                                                                              [@b132-ijn-13-2921]                                                                                                                                   
  PTX-peptide-PEG/TAT-PEG-PE                               PTX                                   MMP selective cleavage                                                      Triggered drug release                                                                              [@b57-ijn-13-2921]                                                                                                                                    
  External                                                 Temperature                           Biotin-PEG-*b*-P(NIPAAm-*co*-HMAAm)                                         MTX                                                                                                 Thermo-responsive deformation of micellar structure                                Triggered drug release                                             [@b133-ijn-13-2921]
  Poly(diEGMA-*co*-OEGMA300)-*b*-PEHMA                     GEM and PTX                           Thermo-reversible phase transition and deformation of micellar structure    Triggered drug release                                                                              [@b134-ijn-13-2921]                                                                                                                                   
  Alginate-*g*-PNIPAAm                                     DOX                                   Thermo-reversible micelle formation                                         Sustained drug release at 37°C                                                                      [@b73-ijn-13-2921]                                                                                                                                    
  P(NIPAAm-*co*-DMAAm)-*b*-PLLA-*b*-P(NIPAAm-*co*-DMAAm)   Curcumin                              Thermo-reversible micelle formation                                         Triggered drug release                                                                              [@b135-ijn-13-2921]                                                                                                                                   
  P(MEO2MA-*co*-OEGMA)-*b*-PLLA-*b*-P(MEO2MA-*co*-OEGMA)   Curcumin                              Thermo-reversible phase transition and micelle formation                    Triggered drug release                                                                              [@b136-ijn-13-2921]                                                                                                                                   
  Magnetic field                                           PEO-PPO-PEO-PLA/SPIONs                DOX⋅HCl                                                                     Ligand-FA and magnetic tumor targeting                                                              Targeted drug delivery                                                             [@b137-ijn-13-2921]                                                
  PCL-PEG/SPIONs                                           DOX                                   Tumor-targeting ligand and magnetic responsiveness                          Targeted drug delivery                                                                              [@b138-ijn-13-2921]                                                                                                                                   
  PCL-PEG/magnetic nanoparticles                           DOX                                   Magnetic heating and thermo-responsiveness                                  Magnetically triggered drug release                                                                 [@b139-ijn-13-2921]                                                                                                                                   
  Light                                                    CPEG-*g*-DNQ                          Coumarin 102                                                                Light-responsive DNQ groups                                                                         Triggered drug release                                                             [@b140-ijn-13-2921]                                                
  SP-hb-PG                                                 Pyrene                                Light-responsive phase transition of SP                                     Triggered drug release                                                                              [@b109-ijn-13-2921]                                                                                                                                   
  HMS\@C18\@HAMAFA-*b*-DDACMM                              Coumarin                              Light-responsive degradation of copolymer                                   Triggered drug release                                                                              [@b141-ijn-13-2921]                                                                                                                                   
  Ultrasound                                               PEO-PPO-PEO (Pluronic P105)           DOX                                                                         Ultrasound-triggered structural transitions                                                         Triggered drug release                                                             [@b142-ijn-13-2921]--[@b144-ijn-13-2921]                           
  PLA-*b*-PEG                                              Nile Red                              Ultrasound-triggered micelle structure breaking                             Triggered dye release                                                                               [@b91-ijn-13-2921]                                                                                                                                    
  PEG-PCL                                                  DOX                                   Ultrasound-triggered microbubble cavitation                                 Triggered drug trafficking into the cell nuclei                                                     [@b92-ijn-13-2921]                                                                                                                                    
  Multi-stimuli                                            pH, redox                             PEG-ss-PTMBPEC                                                              DOX                                                                                                 pH-responsive hydrolysis of acetal bonds and redox-responsive s--s bond cleavage   Redox-and pH-triggered intracellular drug release                  [@b145-ijn-13-2921]
  pH, light                                                P-DOX/P-Cypate                        DOX                                                                         pH-responsive dissociation and light-responsive tunable hyperthermia effect                         pH-triggered prodrug release and light-responsive cytosol drug release             [@b146-ijn-13-2921]                                                
  Redox, light                                             PEO-ss-PS-ONB-PDMAEMA                 Nile Red                                                                    Redox-and photo-responsive cleavage                                                                 Triggered dye release                                                              [@b147-ijn-13-2921]                                                
  Thermal, redox                                           PCL-ss-PDMAEMA                        DOX                                                                         Thermal response of PDMAEMA and redox-responsive s--s bond cleavage                                 Controlled drug release                                                            [@b148-ijn-13-2921]                                                
  pH, redox, light                                         PC-SPMA                               Taxol                                                                       pH-responsive boronate ester, redox-responsive disulfide bonds, and photo-responsive fluorescence   Triggered drug release                                                             [@b149-ijn-13-2921]                                                

**Abbreviations:** PHis, poly(histidine); sbPEI, short branched poly(ethylene imine); mPEG, methoxy PEG; PSDM, polysulfadimethoxine; PTX, paclitaxel; PEG, poly(ethylene glycol); MRI, magnetic resonance imaging; CR-CAs, PEG-PLLA-DTPA-Gd/PEG-PHis; PLA, poly(D,L-lactide); DTPA, diethylenetriaminepentaacetic acid; PDPA, poly(2-(diisopropylamino)ethyl methacrylate); TPGS, D-α-Tocopherol polyethylene glycol 1000 succinate; DOX, doxorubicin; HPAH, hyperbranched polyacylhydrazone; DTX, docetaxel; CTPP, (4-Carboxybutyl) triphenylphosphonium bromide; CSOSA, chitosan-SA; Cela, celastrol; CPP, 1,3-bis(carboxyphenoxy) propane; SA, sebacic acid; HA, hyaluronic acid; OA, octandioic acid; bPEI, branched PEI; AURKA, aurora kinase A; PPE, polyphosphoester; PCL, poly(ε-caprolactone); PLL, poly(L-lysine); MMP, matrix metalloproteinase; PhAc, phenylacetyl; FFAGLDD, Phe-Phe-Ala-Gly-Leu-Asp-Asp; PA, palmitic acid; TAT, trans-activating transcriptional activator; PE, phosphoethanolamine; NIPAAm, N-isopropylacrylamide; HMAAm, N-hydroxymethyl acrylamide; MTX, methotrexate; EGMA, (ethylene glycol) methacrylate; OEGMA, oligo(ethylene glycol) methacrylate; PEHMA, poly(2-ethylhexyl methacrylate); GEM, gemcitabine; DMAAm, *N,N*-dimethylacrylamide; PLLA, poly(L-lactide); MEO~2~MA, 2-(2-methoxyethoxy) ethyl methacrylate; PEO, poly(ethylene oxide); PPO, poly(propylene oxide); SPIONs, superparamagnetic iron oxide nanoparticles; FA, folate; CPEG, comb-like PEG; DNQ, 2-diazo-1,2-naphthoquinone; SP, spiropyran; PG, polyglycerol; HMS, hollow mesoporous spherical particles; C18, octadecyltrimethoxysilane; HAMAFA, 2-hydroxyethylacrylate (HEA)-N-(3-aminopropyl) methacrylamide hydrochloride (APMA)-FA; DDACMM, \[7-(didodecylamino) coumarin-4-yl\] methyl methacrylate; PTMBPEC, poly(2,4,6-trimethoxybenzylidene-pentaerythritol carbonate); PS, polystyrene; ONB, *o*-nitrobenzyl; PDMAEMA, poly(2-(dimethylamino)ethyl methacrylate); PC, pluronic-chitosan; SPMA, spiropyran and phenylboronic acid-conjugated poly(dimethylamino ethyl methacrylate-co-methyl acrylic acid).
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